問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2025-10-18

蘇本華
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

2Cases

2026-03-16 - 2034-01-30

Phase III

Not yet recruiting
Efficacy, safety, and pharmacokinetics of once-weekly subcutaneous cagrilintide 2.4 mg as monotherapy and in combination with subcutaneous semaglutide 2.4 mg (CagriSema) for weight management in overweight or obese children and adolescents.
  • Condition/Disease

    Obesity

  • Test Drug

    Cagrilintide CagriSema Semaglutide

Participate Sites
4Sites

Recruiting4Sites

2018-08-01 - 2022-06-30

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites